Tolerance of Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) Inhibitors in Patients With Self-Reported Statin Intolerance
-
- Erica R. Davidson
- The Ohio State University Wexner Medical Center, Columbus, OH, USA
-
- Melissa J. Snider
- The Ohio State University Wexner Medical Center, Columbus, OH, USA
-
- Kelly Bartsch
- The Ohio State University Wexner Medical Center, Columbus, OH, USA
-
- Andrea Hirsch
- The Ohio State University Wexner Medical Center, Columbus, OH, USA
-
- Junan Li
- The Ohio State University Wexner Medical Center, Columbus, OH, USA
-
- John Larry
- The Ohio State University Wexner Medical Center, Columbus, OH, USA
Description
<jats:sec><jats:title>Background:</jats:title><jats:p> Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been shown to lower atherogenic lipid markers in patients with statin intolerance; however, external validity of these findings is unclear in patients with self-reported statin intolerance. </jats:p></jats:sec><jats:sec><jats:title>Objective:</jats:title><jats:p> The objective of this study was to describe the tolerability of evolocumab and alirocumab in patients with self-reported statin intolerance. Secondary objectives were to describe their efficacy and obtainability. </jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p> A retrospective chart review was completed and included adult patients with self-reported statin intolerance who were prescribed a PCSK9 inhibitor. Patient-reported side effects, laboratory values, and insurance information were collected for assessment of study objectives. </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> During the study period, 55 patients were prescribed PCSK9 inhibitor, 42 started therapy, and 34 had at least 1 follow-up visit. While myalgias occurred in 14.7% (n = 5) of patients, flu-like symptoms in 11.8% (n = 4), and fatigue in 2.9% (n = 1), only 5.9% (n = 2) of prescriptions for PCSK9 inhibitors were discontinued. Low-density lipoprotein cholesterol (LDL-C) was reduced 48.7% (95% confidence interval [CI]: -1.7%-99.1%), and 20 (58.8%) patients achieved a ≥50% reduction in LDL-C. Regarding obtainability, of the 57 prescriptions written, 77.2% (n = 44) required prior authorization and 5.3% (n = 3) were denied by insurance. </jats:p></jats:sec><jats:sec><jats:title>Conclusion:</jats:title><jats:p> PCSK9 inhibitors were well tolerated in patients with self-reported statin intolerance. </jats:p></jats:sec>
Journal
-
- Journal of Pharmacy Practice
-
Journal of Pharmacy Practice 33 (3), 276-282, 2018-09-16
SAGE Publications
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1363670321014286208
-
- ISSN
- 15311937
- 08971900
-
- Data Source
-
- Crossref